ERV-Fc

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients

Retrieved on: 
Tuesday, March 28, 2023
DNA, Clinical trial, Cancer, Immunotherapy, ERV-Fc, Patient, Koala retrovirus, EVX, ERV, Pharmaceutical industry

Recently, Evaxion announced that the Company has used its proprietary AI technology to discover a new treatment opportunity that may broaden cancer immunotherapy.

Key Points: 
  • Recently, Evaxion announced that the Company has used its proprietary AI technology to discover a new treatment opportunity that may broaden cancer immunotherapy.
  • Through new cancer targets, so-called ERVs (endogenous retroviruses), it may become possible to treat cancer patients who have until now been considered unresponsive to immunotherapy.
  • A natural next step is to maximize the value of our unique AI capabilities by focusing on target discovery and validation and early out-licensing opportunities.
  • In addition, the focus on our core will extend our cash runway towards the end of the year.”

AEW UK REIT plc: NAV Update and Dividend Declaration

Retrieved on: 
Thursday, October 21, 2021
LSE, EPS, IPO, EPRA, Contract, NAV, Interim, ERV, Oxford, Collection, Company, ERV-Fc, AEW, Acquisition, Sale, Lithium, Commercial property, Warehouse, AEW UK REIT, AEW UK Investment Management LLP, AEW UK REIT, AEW UK INVESTMENT MANAGEMENT LLP

AEW UK REIT plc (LSE: AEWU) (the "Company"), which directly owns a diversified portfolio of 35 regional UK commercial property assets, announces its unaudited Net Asset Value ("NAV") and interim dividend for the three-month period ended 30 September 2021.

Key Points: 
  • AEW UK REIT plc (LSE: AEWU) (the "Company"), which directly owns a diversified portfolio of 35 regional UK commercial property assets, announces its unaudited Net Asset Value ("NAV") and interim dividend for the three-month period ended 30 September 2021.
  • Interim dividend of 2.00 pence per share for the three months ended 30 September 2021, in line with the targeted annual dividend of 8.00 pence per share.
  • NAV of 174.29 million or 110.01 pence per share as at 30 September 2021 (30 June 2021: 169.69 million or 107.11 pence per share).
  • NAV total return of 4.58% for the quarter (30 June 2021 quarter: 10.04%).